It seems clear that atherogenic dyslipidemia represents and imbalance in cholesterol transport, resulting in more cholesterol being delivered to the blood vessel wall and less being removed. Statin therapy can decrease diabetic patients' coronary event risk to a level comparable to that of untreated persons with-out diabetes. Combining treatments aimed at raising HDL-C with use of a statin is necessary to achieve a favorable outcome for our insulin-resistant patients with atherogenic dyslipidemia.
|Number of pages||4|
|State||Published - Apr 1 2006|
ASJC Scopus subject areas